Suppr超能文献

HER-2/neu表达随时间及在多个转移部位的稳定性。

Stability of HER-2/neu expression over time and at multiple metastatic sites.

作者信息

Niehans G A, Singleton T P, Dykoski D, Kiang D T

机构信息

Laboratory Service, Department of Veterans Affairs Medical Center, Minneapolis, Minn.

出版信息

J Natl Cancer Inst. 1993 Aug 4;85(15):1230-5. doi: 10.1093/jnci/85.15.1230.

Abstract

BACKGROUND

Amplification and over-expression of the HER-2/neu oncogene (also known as c-erbB-2) occurs in 20%-30% of invasive breast carcinomas. The extent to which HER-2/neu expression changes over time in association with tumor progression or is heterogeneous at different metastatic sites has received only limited study.

PURPOSE

Our purpose was to determine whether primary tumors differ from metastases in HER-2/neu protein content or whether metastases are heterogeneous in regard to HER-2/neu expression.

METHODS

In a retrospective study, we examined tumor tissue obtained at autopsy from two to five metastatic organ sites in each of 30 patients who died with metastatic breast carcinoma. Using an immunoperoxidase technique, we stained archival formalin-fixed, paraffin-embedded tissue sections with a monoclonal antibody to the 185-kilodalton protein product (p185) of the HER-2/neu gene.

RESULTS

The tissue from eight of 30 patients showed strong diffuse reactivity for p185 at all metastatic sites examined. Tissues from six patients showed faint staining and tissues from 15 were negative, again with a congruent staining pattern. A single case showed discordant staining, in that two of four metastases showed faint staining, whereas the other two showed strong immunoreactivity. In 14 cases, we were able to obtain paraffin blocks from the original biopsy or surgical resection of the primary breast lesion. For these 14 patients, the average length of time between initial diagnosis and death was 4 years (range, 2-9). There was good correlation between results from autopsy and original surgical tissues.

CONCLUSIONS

Expression of HER-2/neu appears to be relatively stable over time and is generally congruent at different metastatic sites.

IMPLICATIONS

The fact that p185 immunoreactivity is rarely heterogeneous is encouraging, both for the potential use of HER-2/neu-related proteins as serum tumor markers and for innovative therapies targeted at p185 expression.

摘要

背景

HER-2/neu癌基因(也称为c-erbB-2)的扩增和过表达在20%-30%的浸润性乳腺癌中出现。HER-2/neu表达随时间与肿瘤进展相关的变化程度,或在不同转移部位的异质性,仅得到有限的研究。

目的

我们的目的是确定原发性肿瘤与转移瘤在HER-2/neu蛋白含量上是否存在差异,或者转移瘤在HER-2/neu表达方面是否存在异质性。

方法

在一项回顾性研究中,我们检查了30例死于转移性乳腺癌患者尸检时从两到五个转移器官部位获取的肿瘤组织。使用免疫过氧化物酶技术,我们用针对HER-2/neu基因185千道尔顿蛋白产物(p185)的单克隆抗体对存档的福尔马林固定、石蜡包埋组织切片进行染色。

结果

30例患者中有8例的组织在所有检查的转移部位对p185显示出强烈的弥漫性反应。6例患者的组织显示弱阳性染色,15例患者的组织为阴性,同样具有一致的染色模式。1例患者显示不一致的染色,即4个转移瘤中有2个显示弱阳性染色,而另外2个显示强免疫反应性。在14例病例中,我们能够从原发性乳腺病变的原始活检或手术切除中获得石蜡块。对于这14例患者,从初始诊断到死亡的平均时间为4年(范围为2 - 9年)。尸检结果与原始手术组织结果之间具有良好的相关性。

结论

HER-2/neu的表达似乎随时间相对稳定,并且在不同转移部位通常是一致的。

意义

p185免疫反应性很少异质性这一事实令人鼓舞,这对于将HER-2/neu相关蛋白用作血清肿瘤标志物的潜在用途以及针对p185表达的创新疗法而言都是如此。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验